Latest stories
Featured
Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic®...
Press Release, Business Development 12 February 2024
- Hikma launches ePHEDrine Sulfate Injection, USP in the US Press Release, Product 30 December 2024 Hikma launches ePHEDrine Sulfate Injection, USP in the US
- Hikma receives FDA approval and launches the generic version of Victoza®, Liraglutide, in the US Press Release, Product 26 December 2024 Hikma receives FDA approval and launches the generic version of Victoza®, Liraglutide, in the US
- Hikma launches Indomethacin Suppositories in the US Press Release, Product 20 December 2024 Hikma launches Indomethacin Suppositories in the US
- Hikma acquires the rights to a portfolio of Takeda brands for the MENA region Press Release, Product 19 December 2024 Hikma acquires the rights to a portfolio of Takeda brands for the MENA region
Related content